Home » Newsletters » BioWorld Science

BioWorld Science

April 26, 2010

View Archived Issues

GSK claims new AMPA glutamate receptor agonists as antipsychotics

GSK discloses new calcium-sensing receptor antagonists

AstraZeneca discovers novel MAPK p38 alpha inhibitors

PREEMPT trials show benefit of Botox in chronic migraine

Clinical data presented from several GS-9450 studies

Nitazoxanide plus PEG-IFN/RBV beneficial in HCV genotype 1

Merck & Co. describes novel CGRP receptor antagonists

Boehringer Ingelheim identifies new B-raf inhibitors

BATTLE trial identifies biomarkers for personalized lung cancer therapy

Affymax institutes quiet period during analysis of phase III Hematide data

XL-647/sorafenib combination shows promise in preclinical models of HCC

Preclinical data support virodhamine as potential antifibrogenic mediator

CSL withholds distribution of pediatric influenza vaccine in Australia

Pfizer and MMV partner to develop malaria therapeutic in pregnancy

IAVI and Lentigen collaborate on novel AIDS vaccine candidate

Acura and King provide update on FDA advisory committee meeting on Acurox NDA

Ampio seeks to acquire DMI Biosciences

Celtic Pharma evaluates Xerecept in pediatric patients with metastatic brain tumors

Genentech submits supplemental BLA to FDA for Herceptin in stomach cancer

NeoStem and ImmuneRegen collaborate on stem cell technology

Aragon secures financing to advance ARN-509

StemCells advances second clinical trial of HuCNS-SC cells in Batten disease

Icagen to present results on ICA-105665 in epilepsy

Pfizer halts phase III trial of Sutent in liver cancer

Novartis receives E.U. approval for Diovan in children and adolescents with hypertension

European CHMP recommends approval of Daxas for COPD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...